GeneDx Investors Face August Deadline in Securities Class Action

The litigation, pending in the U.S. District Court for the District of Connecticut, centers on claims that GeneDx executives failed to disclose material information regarding the company's fiscal health between April 16, 2025, and May 4, 2026. Tensions peaked following the company's first-quarter report for fiscal year 2026, which revealed a sharp decline in adjusted gross margins and missed revenue targets for both exome and genome product lines.

Investors were further rattled by the disclosure of a $31.2 million impairment loss tied to the acquisition of Fabric Genomics. While GeneDx had previously marketed the AI-driven firm as a transformative engine for recurring revenue, the reality of the integration proved far costlier than projected. Following these revelations, the company slashed its full-year revenue guidance to a range of $475 million to $490 million, down from earlier estimates of $550 million. The market reaction was immediate and severe, wiping out nearly half of the company's share value in a single session.